Infectious Diseases: Cure, Contain & Counter

blog header image

With the first case of MERS hitting the US, the increase of Polio in war zones, and recent outbreak of the Ebola virus in Liberia – infectious diseases are back in the headlines.

It’s not just the ‘exotic’ diseases that pose risk. Not a week goes by without a report of an outbreak of meningitis, measles, mumps and chickenpox – not to mention influenza. There is a strong correlation pointing to lasting effects – that exposure to infectious diseases increases risk of chronic illnesses.

Scientists are looking for cures to new diseases, but also struggling to find new cures for old diseases due to the explosion of antibiotic-resistant microbes and the growing threat of bioterrorism.

The University of Kansas is investing heavily in research to fight infectious disease. Our renowned team of biologists and chemists are identifying novel anti-infective targets, investigating mechanisms of drug resistance and virulence, creating vaccines against viruses and toxins, exploring gene therapies, and synthesizing compounds and natural products for prevention and containment.

We have proven success in working with partners to transform foundational discoveries into approved and broadly available screens, vaccines, and treatments to reduce suffering and stop infections before they start. You can learn about existing technology available for license here

Over the next few months, we will highlight exciting new research at KU including discovering new anti-microbial treatments, drug delivery methods and vaccines.

We look forward to keeping you updated on exciting progress at KU.

August 14, 2014

About the Author

Julie Goonewardene
Former President of KU Innovation and Collaboration and
Former Associate Vice Chancellor for Innovation & Enterprise

Julie Goonewardene is a recognized leader in technology commercialization, business formation and public/private partnerships.  From corporate boardrooms to university research labs, she bring together groups across the spectrum to develop new solutions to medical and business challenges.